- Home
- TNXP vs USAU Comparison
TNXP vs USAU Comparison
Compare TNXP & USAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- USAU
- Stock Information
- Founded
- TNXP 2007
- USAU N/A
- Country
- TNXP United States
- USAU United States
- Employees
- TNXP N/A
- USAU N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- USAU Precious Metals
- Sector
- TNXP Health Care
- USAU Basic Materials
- Exchange
- TNXP Nasdaq
- USAU Nasdaq
- Market Cap
- TNXP 118.2M
- USAU 120.4M
- IPO Year
- TNXP N/A
- USAU N/A
- Fundamental
- Price
- TNXP $18.83
- USAU $11.97
- Analyst Decision
- TNXP Strong Buy
- USAU Strong Buy
- Analyst Count
- TNXP 2
- USAU 2
- Target Price
- TNXP $585.00
- USAU $11.50
- AVG Volume (30 Days)
- TNXP 573.9K
- USAU 412.2K
- Earning Date
- TNXP 05-20-2025
- USAU 03-17-2025
- Dividend Yield
- TNXP N/A
- USAU N/A
- EPS Growth
- TNXP N/A
- USAU N/A
- EPS
- TNXP N/A
- USAU N/A
- Revenue
- TNXP $10,094,000.00
- USAU N/A
- Revenue This Year
- TNXP $12.17
- USAU N/A
- Revenue Next Year
- TNXP $789.15
- USAU N/A
- P/E Ratio
- TNXP N/A
- USAU N/A
- Revenue Growth
- TNXP 29.94
- USAU N/A
- 52 Week Low
- TNXP $6.76
- USAU $4.21
- 52 Week High
- TNXP $672.00
- USAU $11.75
- Technical
- Relative Strength Index (RSI)
- TNXP 53.35
- USAU 66.15
- Support Level
- TNXP $18.55
- USAU $9.56
- Resistance Level
- TNXP $21.99
- USAU $11.14
- Average True Range (ATR)
- TNXP 1.53
- USAU 0.76
- MACD
- TNXP 0.22
- USAU 0.12
- Stochastic Oscillator
- TNXP 58.64
- USAU 98.99
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.